# US 2020/0390847 A1 · Method of treating diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390847 A1
- Document ID: US20200390847A1
- Status: Published application
- Kind: A1
- Application number: 16/881,348
- Filed: 2020-05-22
- Published: 2020-12-17
- Earliest claimed: 2015-02-03
- Assignees: Chiasma, Inc.
- Applicants: Chiasma, Inc.
- Inventors: Roni Mamluk; Sam L. Teichman
- Web page: https://patentgrep.com/patent/US20200390847A1

## CPC

- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/4858: {Organic compounds}
- A61K 38/31: Somatostatins
- A61P 5/06: of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A method of treating acromegaly in a subject, the method comprising:
a) orally administering to the subject at least one dosage form comprising octreotide, wherein the subject is administered an H2-receptor antagonist or an antacid;
b) monitoring IGF-1 and clinical symptoms or biochemical and symptomatic response of the subject; and
c) if IGF-1 is not normal and clinical symptoms are not controlled or biochemical and symptomatic response is not maintained, then increasing the total dose of oral octreotide administered to the subject.

### Claim 22 (depends on 21)

The method of claim 21, wherein the amount of octreotide in each dosage form is 20 mg.

### Claim 23 (depends on 21)

The method of claim 21, wherein the administering of octreotide occurs at least 1 hour before a meal or at least 2 hours after a meal.

### Claim 24 (depends on 21)

The method of claim 21, wherein the dosage form comprises an oily suspension which is formulated into a capsule.

### Claim 25 (depends on 24)

The method of claim 24, wherein the capsule is enterically coated.

### Claim 26 (depends on 21)

The method of claim 21, wherein the administering of octreotide occurs twice daily.

### Claim 27 (depends on 26)

The method of claim 26, wherein the subject is dosed in the morning and in the evening, comprising a first and second administration.

### Claim 28 (depends on 27)

The method of claim 27, wherein the first administration includes one or two dosage forms and the second administration includes one or two dosage forms.

### Claim 29 (depends on 27)

The method of claim 27, wherein the first administration includes one dosage form and the second administration includes one dosage form.

### Claim 30 (depends on 27)

The method of claim 27, wherein the first administration includes two dosage forms and the second administration includes one dosage form.

### Claim 31 (depends on 27)

The method of claim 27, wherein the first administration includes two dosage forms and the second administration includes two dosage forms.

### Claim 32 (depends on 21)

The method of claim 21, wherein one dosage form is administered twice a day.

### Claim 33 (depends on 21)

The method of claim 21, wherein two dosage forms are administered twice a day.

### Claim 34 (depends on 21)

The method of claim 21, wherein one dosage form is administered once a day and two dosage forms are administered once a day.

### Claim 35 (depends on 21)

The method of claim 21, wherein the total amount of octreotide administered per day to the subject is 40 mg, 60 mg, or 80 mg.
